On 10 March 2014, the European Commission (“Commission”) published a report which details the results of an assessment of external reference pricing on pricing and reimbursement decisions for medicinal products in the European Union (“EU”). The report was produced and funded under the EU Health Programme 2008-2013.
The report identifies the main parameters which impact the pricing and reimbursement decisions for medicinal products within external reference pricing systems. These parameters include the effects of pricing and reimbursement decisions for medicinal products taken in one EU Member State on pricing and reimbursement decisions in other EU Member States.
Based on a simulation model, the assessment identified these main parameters in all 28 EU Member States. The report also briefly examines the external reference pricing processes in non-EU countries such as Australia, Canada, Japan and Turkey.